Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 12, 2025
Discovery & Translation

Science Spotlight: Killing the mesenchymal precursors that drive cancer progression

BioCentury’s roundup of translational innovations also includes blood detection of pregnancy complications, BBB-crossing antibodies, and more
BioCentury | Jan 28, 2025
Distillery Therapeutics

An allosteric MYO9A and MYO9B inhibitor for cancer metastasis

BioCentury | Dec 18, 2024
Product Development

Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report

Plus: Readouts from Sanofi-Teva, Bicycle and more
BioCentury | Nov 26, 2024
Deals

Kyowa Kirin brings global reach to Kura’s menin program via licensing deal

Also in BioCentury’s Deals Report: Novartis buys gene therapy play Kate, Telix buys FAP-targeting theranostics, and more
BioCentury | Aug 8, 2024
Discovery & Translation

Science Spotlight: Stopping herpes from entering neurons, tissue-specific nanoparticles, and more

BioCentury’s roundup of translational innovations
BioCentury | May 24, 2024
Finance

Public Equity Report: Investors see Cytokinetics’ moves as doubt for M&A

Plus: IPO updates from Sunho, Rapport; Bicycle’s massive PIPE; Dyne’s opportunistic follow-on; and more
BioCentury | Apr 20, 2024
Product Development

Triple-negative breast cancer attracts target innovation at AACR 

BioCentury identifies 44 new targets presented at meeting
BioCentury | Feb 8, 2024
Product Development

Bristol Myers’ growing challenge

The clinical and commercial successes needed for Bristol Myers to navigate its upcoming patent cliff
BioCentury | Jan 3, 2024
Data Byte

Comparing Cytokinetics’ aficamten with BMS’s Camzyos

Aficamten appears to have slight edge over Camzyos in increasing peak oxygen uptake
Items per page:
1 - 10 of 249
Username